<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02282176</url>
  </required_header>
  <id_info>
    <org_study_id>C12-75</org_study_id>
    <secondary_id>2013-003889-14</secondary_id>
    <nct_id>NCT02282176</nct_id>
  </id_info>
  <brief_title>TINN2: Treat Infection in NeoNates 2</brief_title>
  <acronym>TINN2</acronym>
  <official_title>A Randomised, Placebo Controlled Trial of Azithromycin for the Prevention of Chronic Lung Disease of Prematurity in Preterm Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Inserm-Transfert (IT)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Liverpool</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cardiff University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Nottingham</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Heinrich-Heine-Universität Düsseldorf (UDUS)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mario Negri Institute (IRFMN)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Advanced Biological Laboratories ABL (ABL SA)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Simcyp Limited (SimCyp)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Only For Children Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Ulm</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier Chrétien (CHC)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Semmelweis University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut National de la Santé Et de la Recherche Médicale, France</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the TINN2 study is to evaluate the efficacy of azithromycin in prevention of
      bronchopulmonary dysplasia in preterm neonates.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In contrast to the situation in adults, most medicines used to treat the children of Europe
      have not been tested and are not authorised for use in children. In particular, 46% medicines
      prescribed to children in hospital are either unlicensed for their age group or, if licensed,
      are prescribed off label. Of the children who receive at least one medication in hospital,
      67% receive an unlicensed or off-label drug, and in the context of intensive care, this rises
      to up to 90% of patients.

      The new Paediatric Regulation entered into force in early 2007 ensure that medicines for use
      in children are of high quality, ethically evaluated and authorised appropriately. The
      Paediatric-Use Marketing Authorisation (PUMA) is a new type of marketing authorisation for
      drugs not covered by a patent, already available on the market for adults. PUMA applies to
      medicines lacking information and/or appropriate formulation for children of all ages.

      Thus, the European Medicines Agency (EMA) has published a list of drugs, which azithromycin
      belongs, as priority medicinal products needing an evaluation in the paediatric population.

      Bronchopulmonary dysplasia (BPD) is a specific disease of prematurity accompanied by
      pulmonary inflammation. Multiple factors may contribute to the occurrence of BPD. In infants
      who are at risk of developing CLD, one frequent finding is colonisation of the preterm lung
      with the microbe Ureaplasma.

      Two Meta-Analyses and recent studies have suggested an association between the presence of
      pulmonary Ureaplasma and the development of BPD.

      Azithromycin is a macrolide antibiotic active against Ureaplasma spp with anti-inflammatory
      properties. Thus, it may be effective in reducing the severity of bronchopulmonary diseases
      in which both infection and inflammation play a role.

      TINN2 project: the aim of the TINN2 study is to evaluate the efficacy of azithromycin in
      prevention of bronchopulmonary dysplasia in preterm neonates. TINN2 is a consortium involving
      European leaders in neonatology, paediatric pharmacology, methodology and several SMEs that
      will establish links with ethical bodies and regulatory authorities.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of surviving infants without CLD (Chronic Lung Disease) in the azithromycin treatment group when compared to placebo at 36 weeks post-menstrual age.</measure>
    <time_frame>36 weeks post-menstrual age</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality rate (at 28 days, 36 weeks PMA, 2 years)</measure>
    <time_frame>28 days, 36 weeks PMA, 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of CLD (Chronic Lung Disease) according to NIH definition</measure>
    <time_frame>36 weeks PMA</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiology assessment</measure>
    <time_frame>Baseline and days 5, 10, 21</time_frame>
    <description>Microbiology assessment at baseline and days 5, 10, 21:
Pulmonary colonisation by Ureaplasma spp. and Mycoplasma spp. (respiratory culture of endotracheal/nasopharyngeal aspirates and nasogastric aspirates (nasogastric only for Ureaplasma spp. at baseline) and species-specific quantitative PCR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammation Markers</measure>
    <time_frame>Baseline and days 5, 10, 21</time_frame>
    <description>Subroup of patients:
Inflammatory markers at baseline and days 5, 10, 21 in plasma and bronchoalveolar lavage
Identification of the following: IL-1, IL-6, IL-8, TNF-a, MCP-1, PMN/Am/TCC, C5a.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of positive pressure respiratory support (i.e. conventional mechanical ventilation, nasal ventilation, continuous positive airway pressure, CPAP) and supplemental oxygen</measure>
    <time_frame>up to 36 weeks PMA</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Emergence of resistance to azithromycin in Ureaplasma spp. isolated from endotracheal or nasopharyngeal samples at baseline, days 5, 10 and 21</measure>
    <time_frame>Baseline, days 5, 10 and 21</time_frame>
    <description>On each positive PCR a culture will be performed. Then, an antibiotic susceptibility testing upon positive cultures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resistance to azithromycin among microbes isolated from stool or rectal swab obtained at baseline and day 21</measure>
    <time_frame>Baseline and day 21</time_frame>
    <description>Antibiotic susceptibility testing on any identified microbes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations</measure>
    <time_frame>days 1, 3, 6 as required</time_frame>
    <description>Each patients to be allocated two sample timepoints from the following schedule:
Sample1:
1 sample within 5 min after the end of dose administration (day 1) Or 1 sample at 6 hours after start of infusion (day 1) Or 1 sample at 12 hours after start of infusion (day 1)
Sample 2:
1 sample at 48 hours - just prior to the third administration (day 3) Or 1 sample at 144 hours- just prior to the sixth administration (day 6)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exposure to antibiotics other than azithromycin during the hospital stay</measure>
    <time_frame>up to 36weeks PMA</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of complications of prematurity</measure>
    <time_frame>24 months</time_frame>
    <description>Development of complications of prematurity: Nosocomial infection (sepsis, meningitis, pneumonia); intraventricular haemorrhage; necrotising enterocolitis; retinopathy of prematurity; patent ductus arteriosus; pulmonary hemorrhage, pneumothorax and pulmonary interstitial emphysema during hospital stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Adverse Events</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with dysrhythmic episodes and QTc interval</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-Reactive Protein</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurodevelopmental assessment: Assessment of neurodevelopment using the 3rd edition of the Bayley Scales of Infant Development at the corrected age of 24 months</measure>
    <time_frame>24 months</time_frame>
    <description>Long-term follow up at the corrected age of 24 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory function assessment: Assessment of respiratory symptoms using a validated International Study of Asthma and Allergies in Childhood (ISAAC) questionnaire</measure>
    <time_frame>24 months</time_frame>
    <description>Long-term follow up at the corrected age of 24 months</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Bronchopulmonary Dysplasia</condition>
  <arm_group>
    <arm_group_label>Azithromycin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10mg/kg azithromycin IV daily (administered over a period of at least one 1 hour) for a period of 10 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo IV daily (administered over a period of at least one 1 hour) for a period of 10 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin</intervention_name>
    <description>Azithromycin IV 10mg/kg daily for 10 days</description>
    <arm_group_label>Azithromycin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Azithromycin placebo (5% Dextrose) daily for 10 days</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>5% Dextrose</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Pre-term, 28w + 6d gestational age (i.e. 28 weeks and 6 days, including infants born
             as one of a multiple birth)

          2. Requirement for respiratory support within 12hrs of birth (intubated, or by
             noninvasive mechanical ventilation including continuous positive airway pressure)

          3. Presence of an indwelling intravenous line for drug administration

          4. Inborn, or born at site within the recruiting centre's neonatal network where follow
             up will be possible

        Exclusion Criteria:

          1. In the opinion of the PI, babies unlikely to survive until 48 hours after birth

          2. Exposure to another macrolide antibiotic

          3. Presence of major surgical or congenital abnormalities (not including patent ductus
             arteriosus or patent foramen ovale)

          4. Infants born as part of a multiple pregnancy of three or more (i.e. triplets or more)

          5. Contraindication of azithromycin as specified in the summary of characteristics of the
             product.

          6. Participation in other clinical trials involving Investigational Medicinal Products
             (IMPs)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>23 Weeks</minimum_age>
    <maximum_age>28 Weeks</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sailesh Kotecha</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardiff University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Hospitalier Chrétien (CHC)</name>
      <address>
        <city>Liège</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Assistance Publique Hôpitaux de Paris (APHP)</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inserm-Transfert (IT)</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut National de la Santé et de la Recherche Médicale (INSERM)</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Only for children pharmaceuticals (04CP)</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heinrich-Heine-Universität Düsseldorf (UDUS)</name>
      <address>
        <city>Dusseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Ulm (UUlm)</name>
      <address>
        <city>Ulm</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Semmelweis University Budapest, Faculty of Medicine (SOTE)</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pandy Kalman County Hospital</name>
      <address>
        <city>Gyula</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mario Negri Institute (IRFMN)</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Biological Laboratories ABL (ABL SA)</name>
      <address>
        <city>Luxembourg</city>
        <country>Luxembourg</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus-University Medical Center (ERAMUS)</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska Institutet (KI)</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiff University (CU)</name>
      <address>
        <city>Cardiff</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Liverpool (UOL)</name>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Simcyp Limited (SimCyp)</name>
      <address>
        <city>Sheffield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Luxembourg</country>
    <country>Netherlands</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://tinn2-project.org/</url>
    <description>TINN2 website</description>
  </link>
  <reference>
    <citation>Turner MA, Jacqz-Aigrain E, Kotecha S. Azithromycin, Ureaplasma and chronic lung disease of prematurity: a case study for neonatal drug development. Arch Dis Child. 2012 Jun;97(6):573-7. doi: 10.1136/adc.2010.195180. Epub 2011 Jun 22. Review.</citation>
    <PMID>21697219</PMID>
  </reference>
  <reference>
    <citation>Pansieri C, Pandolfini C, Elie V, Turner MA, Kotecha S, Jacqz-Aigrain E, Bonati M. Ureaplasma, bronchopulmonary dysplasia, and azithromycin in European neonatal intensive care units: a survey. Sci Rep. 2014 Feb 12;4:4076. doi: 10.1038/srep04076.</citation>
    <PMID>24518104</PMID>
  </reference>
  <reference>
    <citation>Lowe J, Watkins WJ, Edwards MO, Spiller OB, Jacqz-Aigrain E, Kotecha SJ, Kotecha S. Association between pulmonary ureaplasma colonization and bronchopulmonary dysplasia in preterm infants: updated systematic review and meta-analysis. Pediatr Infect Dis J. 2014 Jul;33(7):697-702. doi: 10.1097/INF.0000000000000239. Review.</citation>
    <PMID>24445836</PMID>
  </reference>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 17, 2014</study_first_submitted>
  <study_first_submitted_qc>November 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2014</study_first_posted>
  <last_update_submitted>February 24, 2016</last_update_submitted>
  <last_update_submitted_qc>February 24, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neonates</keyword>
  <keyword>Preterm</keyword>
  <keyword>Azithromycin</keyword>
  <keyword>Ureaplasma</keyword>
  <keyword>Chronic Lung disease</keyword>
  <keyword>Bronchopulmonary dysplasia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchopulmonary Dysplasia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

